Our Technology

We have developed a series of Next-Generation Sequencing cancer products optimized for reimbursement, while maximizing clinical utility and the number of patients we help. We transfer our technology into partner labs, empowering clinical facilities to execute world-leading mutation testing for their cancer patients. Through remote and centralized Software as a Service (SaaS) cloud based analytics platforms, we provide an informatics software suite covering the full stack of molecular and computational quality assurance, genome analytics, mutation interpretation and report generation.


We develop and distribute medically necessary and reimbursable tests.

Contextual Genomics’ diagnostic tests are best in class clinical grade cancer assays that digitize biologic samples. We develop and distribute reimbursable tests that are designed to be inexpensive, medically necessary, allow for rapid scaling, and facilitate the collection of longitudinal patient data by monitoring tumour and blood. Local optimization and validation of the tests for business and medical reasons occurs within each of our partners facilities.

Contextual Genomics’ medically necessary reimbursable tests, standardized operating procedures (SOP), assays and standardized analytics ensures the consistency and quality of the data and derivative clinical reports. The test provides a robust data collection source that is automated, centrally monitored, quality assured and is integrated into all our products.


FIND IT™ : Detecting Mutations in Solid Tumour Tissue

Launched in 2016, the Find It™ Test focuses on known mutations in most solid tumour cancers which are treatable with current therapies or Phase 3 investigational treatments. The results of the assay identify therapeutic targets for patients, acquired drug resistance mutations, and mutations with prognostic and diagnostic implications for patient care. The Find It™ Test leads to personalized treatment for patients.

FIND IT™ focuses on more than 146 hotspots and 23 exons in 30 known cancer genes, as listed in Table I. The assay is performed on DNA extracted from formalin-fixed paraffin embedded (FFPE) solid tumour cancers. The results of the assay are presented in a comprehensive report that includes histopathology and interpretation of the sequencing results. Interpretation of the results may include matching of mutations with locally approved drugs, review of recommendations from the National Comprehensive Cancer Network (NCCN), review of the literature, and identification of suitable clinical trials.

FOLLOW IT™ : Detecting Mutations in Plasma

Soon to be available, the Follow It™ Test detects mutations in circulating tumour DNA (ctDNA) derived from plasma. Results from FOLLOW IT™ inform patients and oncologists of treatment response and relapse/remission of disease over time.

Quality Assurance with QUALITY NEXUS™

Our products are embedded with our patented molecular and computational quality assurance platform QUALITY NEXUS™ to enable robust detection of mutations across the full range of diagnostic clinical samples collected in routine pathology workflows. QUALITY NEXUS™ provides the highest level of quality assurance for the tests, safeguarding patients and pinpointing the optimal treatment for their cancer.

QUALITY NEXUS™ permits “best in class” detection of low frequency mutations through the use of a large number of thermodynamically balanced sets of proprietary ‘barcodes’.  By using a machine learning approach for SNV calling and barcode based analysis, QUALITY NEXUS™ creates an opportunity to infer molecular diversity indices and distinguish artifacts from true mutations.

Genome Analytics Platform and Interpretation Engine.

Contextual Genomics has developed a robust, accurate and high-throughput cloud based bioinformatics system for the identification and clinical interpretation of mutations from Next-Generation Sequencing. Our bioinformatics system is distributed internationally through a Software as a Service (SaaS) licensing model.

The system includes clinically validated, proprietary bioinformatics tools and curated databases. The system is fully automated, scalable, secure, traceable and functions in a high throughput production mode using cloud computing.

Diagnostic cancer data is generated at scale using distributed testing coupled with centralized cloud based analytics.

Contextual Genomics is both driving and facilitating the shift towards personalized cancer care. Our analytics system enables us to collect longitudinal patient data by monitoring tumour and blood samples. Interrogation of our aggregated data set provides a more complete picture of cancer facilitating the treatment decision making process.

The variety, volume and veracity of the data creates the knowledge needed to drive new biomedical discoveries and inform and enable precision medical care. Aggregating large sets of data will provide a more complete, longitudinal picture of cancer.